Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jacob Torre

Physician Assistant Fort Worth, TX Physician Assistant

NPI 1679195978 CMS profile 11286810

1701 River Run Ste 1118, Fort Worth, TX 76107

Open in the dashboard

General payments

$14,614

798 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jacob Torre of Fort Worth, TX is reported in the CMS Open Payments database as having received $14,614 across 798 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,199 58
2024 General $1,731 78
2023 General $4,338 239
2022 General $3,787 231
2021 General $3,559 192

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jacob Torre
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Jacob Torre were reported at $1,199. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Jacob Torre Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $3,559 $132 $37–$438 $132
2022 $3,787 $155 $48–$522 $149
2023 $4,338 $167 $52–$557 $160
2024 $1,731 $178 $55–$600 $164
2025 $1,199 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,759 136 payments
  2. ITI, Inc. $1,541 104 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $1,285 72 payments
  4. Teva Pharmaceuticals USA, Inc. $1,104 40 payments
  5. Supernus Pharmaceuticals, Inc. $1,064 51 payments
  6. Otsuka America Pharmaceutical, Inc. $917 61 payments
  7. Lundbeck LLC $831 48 payments
  8. Corium, Inc. $804 47 payments
  9. Neos Therapeutics, LP $751 49 payments
  10. Tris Pharma Inc $649 37 payments
  11. Other $2,909 153 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $14,464 795 payments
  2. Education $150 3 payments
Products named General payments · program years 2021–2025
  1. VRAYLAR Neuroscience $2,053 103 payments
  2. CAPLYTA $1,495 101 payments
  3. TRINTELLIX $1,285 72 payments
  4. AUSTEDO $1,007 39 payments
  5. Azstarys $804 47 payments
  6. Adzenys XR-ODT $720 47 payments
  7. REXULTI Psychiatry $718 48 payments
  8. VRAYLAR Neuroscience $706 33 payments
  9. REXULTI Psychiatry $655 36 payments
  10. QELBREE $567 40 payments
  11. Other $5,899 315 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

798 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record